Show simple item record

Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention

dc.contributor.authorYoon, Ju Yoon
dc.contributor.authorChapel, David B
dc.contributor.authorGoebel, Emily
dc.contributor.authorQian, Xiaohua
dc.contributor.authorMito, Jeffrey K
dc.contributor.authorHorowitz, Neil S
dc.contributor.authorMiron, Alexander
dc.contributor.authorSoong, T Rinda
dc.contributor.authorXian, Wa
dc.contributor.authorCrum, Christopher P
dc.date.accessioned2022-07-05T21:00:24Z
dc.date.available2023-08-05 17:00:20en
dc.date.available2022-07-05T21:00:24Z
dc.date.issued2022-07
dc.identifier.citationYoon, Ju Yoon; Chapel, David B; Goebel, Emily; Qian, Xiaohua; Mito, Jeffrey K; Horowitz, Neil S; Miron, Alexander; Soong, T Rinda; Xian, Wa; Crum, Christopher P (2022). "Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention." The Journal of Pathology 257(3): 255-261.
dc.identifier.issn0022-3417
dc.identifier.issn1096-9896
dc.identifier.urihttps://hdl.handle.net/2027.42/172948
dc.description.abstractThe current theory of carcinogenesis for the deadliest of ‘ovarian’ cancers—high-grade serous carcinoma (HGSC)—holds that the malignancy develops first in the fallopian tube and spreads to the ovaries, peritoneum, and/or regional lymph nodes. This is based primarily on the observation of early forms of serous neoplasia (serous tubal intraepithelial lesions [STILs], and serous tubal intraepithelial carcinomas [STICS]) in the fimbria of women undergoing risk reduction surgery. However, these lesions are uncommon in the general population, confer a low risk (5%) of HGSC following their removal in at-risk women with germ-line BRCA1/2 mutations, and require 4 or more years to recur as intraperitoneal HGSC. These features suggest that isolated STILs and STICs behave as precursors, with uncertain cancer risk rather than carcinomas. Their evolution to HGSC within, or after, escape from the tube could proceed stepwise with multiple biologic events; however, it is unclear whether tubal or ovarian HGSCs encountered in the setting of advanced disease evolved in the same fashion. The latter scenario could also be explained by a ‘catastrophic’ model in which STICs suddenly develop with invasive and metastatic potential, overwhelming or obscuring the site of origin. Moreover, a similar model might explain the sudden emergence of HGSC in the peritoneal cavity following escape of precursor cells years before. Long-term follow-up data from opportunistic or prophylactic salpingectomy should shed light on where malignant transformation occurs, as well as the timeline from precursor to metastatic HGSC. © 2022 The Pathological Society of Great Britain and Ireland.
dc.publisherJohn Wiley & Sons, Ltd
dc.subject.otherfallopian tube
dc.subject.otherprimary peritoneal carcinoma
dc.subject.otherchromothripsis
dc.subject.otherhigh-grade serous carcinoma
dc.subject.otherprevention
dc.subject.otherovary
dc.titleGenomic catastrophe, the peritoneal cavity and ovarian cancer prevention
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPathology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172948/1/path5891.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172948/2/path5891_am.pdf
dc.identifier.doi10.1002/path.5891
dc.identifier.sourceThe Journal of Pathology
dc.identifier.citedreferenceWu RC, Wang P, Lin SF, et al. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. J Pathol 2019; 248: 41 – 50.
dc.identifier.citedreferencePatrono MG, Iniesta MD, Malpica A, et al. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review. Gynecol Oncol 2015; 139: 568 – 572.
dc.identifier.citedreferenceLabidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 2017; 8: 1093.
dc.identifier.citedreferenceJarboe EA, Pizer ES, Miron A, et al. Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol 2009; 22: 345 – 350.
dc.identifier.citedreferenceChapel D, Robinson D, Goebel E, et al. Landscape of putative precursors to high grade serous carcinoma (HGSC) in the female genital tract. Mod Pathol 2020; 30 ( suppl 2 ): 1027.
dc.identifier.citedreferenceChen F, Gaitskell K, Garcia MJ, et al. Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review. BJOG 2017; 124: 872 – 878.
dc.identifier.citedreferenceBrown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009; 6: e1000114.
dc.identifier.citedreferenceStanciu PI, Ind TEJ, Barton DPJ, et al. Development of peritoneal carcinoma in women diagnosed with serous tubal intraepithelial carcinoma (STIC) following risk-reducing salpingo-oophorectomy (RRSO). J Ovarian Res 2019; 12: 50.
dc.identifier.citedreferenceBlok F, Dasgupta S, Dinjens WNM, et al. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: prevalence of invasive and in-situ carcinoma, with follow-up. Gynecol Oncol 2019; 153: 326 – 334.
dc.identifier.citedreferenceRassy E, Assi T, Boussios S, et al. Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered. Ann Transl Med 2020; 8: 1709.
dc.identifier.citedreferenceParmley TH, Woodruff JD. The ovarian mesothelioma. Am J Obstet Gynecol 1974; 120: 234 – 241.
dc.identifier.citedreferenceSeidman JD, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011; 120: 470 – 473.
dc.identifier.citedreferenceSoong TR, Howitt BE, Miron A, et al. Evidence for lineage continuity between early serous proliferations (ESPs) in the fallopian tube and disseminated high-grade serous carcinomas. J Pathol 2018; 246: 344 – 351.
dc.identifier.citedreferenceKuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226: 421 – 426.
dc.identifier.citedreferenceNik NN, Vang R, Shih IM, et al. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol 2014; 9: 27 – 45.
dc.identifier.citedreferenceKelloff GJ, Schilsky RL, Alberts DL, et al. Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res 2004; 10: 3908 – 3918.
dc.identifier.citedreferenceAhmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221: 49 – 56.
dc.identifier.citedreferenceVang R, Levine DA, Soslow RA, et al. Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in The Cancer Genome Atlas ovarian study. Int J Gynecol Pathol 2016; 35: 48 – 55.
dc.identifier.citedreferenceMilea A, George SHL, Matevski D, et al. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma. Mod Pathol 2014; 27: 991 – 1001.
dc.identifier.citedreferencePhillips V, Kelly P, McCluggage WG. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma. Int J Gynecol Pathol 2009; 28: 179 – 186.
dc.identifier.citedreferencePatch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015; 521: 489 – 494.
dc.identifier.citedreferenceCancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609 – 615.
dc.identifier.citedreferenceHua Y, Choi PW, Trachtenberg AJ, et al. Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma. Oncotarget 2016; 7: 66077 – 66086.
dc.identifier.citedreferenceKim J, Coffey DM, Creighton CJ, et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A 2012; 109: 3921 – 3926.
dc.identifier.citedreferenceKorbel JO, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. Cell 2013; 152: 1226 – 1236.
dc.identifier.citedreferenceCortés-Ciriano I, Lee JJ, Xi R, et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet 2020; 52: 331 – 341.
dc.identifier.citedreferenceRatnaparkhe M, Wong JKL, Wei PC, et al. Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. Nat Commun 2018; 9: 4760.
dc.identifier.citedreferenceRausch T, Jones DTW, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148: 59 – 71.
dc.identifier.citedreferenceChan JK, Urban R, Capra AM, et al. Ovarian cancer rates after hysterectomy with and without salpingo-oophorectomy. Obstet Gynecol 2014; 123: 65 – 72.
dc.identifier.citedreferenceFalconer H, Yin L, Grönberg H, et al. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 2015; 107: dju410.
dc.identifier.citedreferenceAmuzu S, Fu L, Demko N, et al. Long-term tumour dormancy in a BRCA1 heterozygote. J Med Genet. 2022. https://doi.org/10.1136/jmedgenet-2021-108269
dc.identifier.citedreferenceHenderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer: An Updated Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 157. AHRQ Publication No. 17-05231-EF-1. Agency for Healthcare Research and Quality: Rockville, MD, 2018.
dc.identifier.citedreferencePrat J, D’Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol 2018; 80: 11 – 27.
dc.identifier.citedreferenceCannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519 – 2529. Erratum in: N Engl J Med 2005; 352: 104.
dc.identifier.citedreferenceKing MC. “ The race” to clone BRCA1. Science 2014; 343: 1462 – 1465.
dc.identifier.citedreferenceSchlosshauer PW, Cohen CJ, Penault-Llorca F, et al. Prophylactic oophorectomy: a morphologic and immunohistochemical study. Cancer 2003; 98: 2599 – 2606.
dc.identifier.citedreferenceFolkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109: 168 – 173.
dc.identifier.citedreferenceBarakat RR, Federici MG, Saigo PE, et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 2000; 89: 383 – 390.
dc.identifier.citedreferenceCraig E, Clarke R, Rushton G, et al. Serous tubal intraepithelial carcinoma (STIC)-like lesions arising in ovarian serous cystadenofibroma: report of 2 cases. Int J Gynecol Pathol 2015; 34: 535 – 540.
dc.identifier.citedreferencePothuri B, Leitao MM, Levine DA, et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One 2010; 5: e10358.
dc.identifier.citedreferenceSaijad Y. Development of the genital ducts and external genitalia in the early human embryo. J Obstet Gynaecol Res 2010; 36: 929 – 937.
dc.identifier.citedreferenceZweemer RP, van Diest PJ, Verheijen RH, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000; 76: 45 – 50.
dc.identifier.citedreferencePiek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451 – 456.
dc.identifier.citedreferenceFinch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006; 100: 58 – 64.
dc.identifier.citedreferenceLeeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002; 87: 52 – 56.
dc.identifier.citedreferenceCass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 2005; 106: 1327 – 1334.
dc.identifier.citedreferenceMedeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230 – 236.
dc.identifier.citedreferenceVang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol 2012; 31: 243 – 253.
dc.identifier.citedreferenceConner JR, Meserve E, Pizer E, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol 2014; 132: 280 – 286.
dc.identifier.citedreferencePowell CB, Swisher EM, Cass I, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol 2013; 129: 364 – 371.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.